Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash from Operations (2016 - 2025)

ImmunityBio (IBRX) has disclosed Cash from Operations for 12 consecutive years, with 70300000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 17.43% to 70300000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 304900000.0, a 22.07% increase, with the full-year FY2025 number at 304900000.0, up 22.07% from a year prior.
  • Cash from Operations was 70300000.0 for Q4 2025 at ImmunityBio, down from 68949000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 60469000.0 in Q1 2021 to a low of 115271000.0 in Q4 2023.
  • A 5-year average of 83741050.0 and a median of 82455000.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: tumbled 96.58% in 2021, then soared 30.19% in 2025.
  • ImmunityBio's Cash from Operations stood at 71639000.0 in 2021, then decreased by 26.64% to 90727000.0 in 2022, then fell by 27.05% to 115271000.0 in 2023, then increased by 26.14% to 85144000.0 in 2024, then grew by 17.43% to 70300000.0 in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Cash from Operations are 70300000.0 (Q4 2025), 68949000.0 (Q3 2025), and 79746000.0 (Q2 2025).